

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 13, 2025

## Caki-1

RRID:CVCL\_0234

Type: Cell Line

---

### Proper Citation

(RRID:CVCL\_0234)

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0234](https://web.expasy.org/cellosaurus/CVCL_0234)

**Proper Citation:** (RRID:CVCL\_0234)

**Sex:** Male

**Defining Citation:** [PMID:327080](#), [PMID:571047](#), [PMID:833871](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:7591954](#), [PMID:9290701](#), [PMID:10700174](#), [PMID:10723130](#), [PMID:10929426](#), [PMID:11146448](#), [PMID:15604581](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17212712](#), [PMID:17804913](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22949125](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24477694](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30260228](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:37668370](#)

**Comments:** Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E), Middle East respiratory syndrome-related coronavirus (MERS-CoV), influenza A virus and respiratory syncytial virus (RSV) (PubMed=37668370)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=37668370)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line

Encyclopedia - CCLE).

**Category:** Cancer cell line

**Name:** Caki-1

**Synonyms:** CAKI-1, CaKi-1, caki-1, CAKI.1, CAKI 1, CAKI1, Caki1

**Cross References:** BTO:BTO\_0003204, CLO:CLO\_0002175, CLO:CLO\_0002176, EFO:EFO\_0002149, MCCL:MCC:0000123, CLDB:cl623, CLDB:cl5175, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-46, BioGRID\_ORCS\_Cell\_line:582, BioSample:SAMN01821541, BioSample:SAMN01821674, BioSample:SAMN03473223, BioSample:SAMN10987640, cancercellines:CVCL\_0234, CancerTools:161903, CCRID:1101HUM-PUMC000244, CCRID:3101HUMSCSP5064, CCRID:3101HUMTCHu135, Cell\_Model\_Passport:SIDM00941, ChEMBL-Cells:CHEMBL3307522, ChEMBL-Targets:CHEMBL614067, CLS:300149, Cosmic:687940, Cosmic:801356, Cosmic:849379, Cosmic:874611, Cosmic:875871, Cosmic:897463, Cosmic:905963, Cosmic:974303, Cosmic:979705, Cosmic:1044261, Cosmic:1092594, Cosmic:1305375, Cosmic:1312363, Cosmic:1998436, Cosmic:2036675, Cosmic:2301558, Cosmic:2520632, Cosmic-CLP:905963, DepMap:ACH-000433, DSMZ:ACC-142, DSMZ:ACC-731, DSMZCellDive:ACC-731, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905963, GEO:GSM2147, GEO:GSM50229, GEO:GSM50293, GEO:GSM743483, GEO:GSM750816, GEO:GSM799374, GEO:GSM799437, GEO:GSM846288, GEO:GSM886902, GEO:GSM887967, GEO:GSM1153447, GEO:GSM1177994, GEO:GSM1177995, GEO:GSM1181288, GEO:GSM1181368, GEO:GSM1669644, GEO:GSM2124663, IARC\_TP53:21041, IGRhCellID:Caki1, IPD-IMGT/HLA:13865, IZSLER:BS TCL 108, JCRB:JCRB0801, KCB:KCB 200850YJ, KCLB:30046, LiGeA:CCLE\_484, LINCX\_LDP:LCL-1774, MetaboLights:MTBLS737, NCI-DTP:CAKI-1, PharmacDB:CAKI1\_163\_2019, PRIDE:PXD003105, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL\_0234, PubChem\_Cell\_line:CVCL\_0234, RCB:RCB1985, SKY/M-FISH/CGH:2790, TKG:TKG 0436, Wikidata:Q54808374

**ID:** CVCL\_0234

**Record Creation Time:** 20220427T215438+0000

**Record Last Update:** 20250131T100358+0000

---

## Ratings and Alerts

No rating or validation information has been found for Caki-1.

**Warning:** Discontinued: RCB; RCB1985

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA

methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E), Middle East respiratory syndrome-related coronavirus (MERS-CoV), influenza A virus and respiratory syncytial virus (RSV) (PubMed=37668370)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=37668370)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: DSMZ; ACC-142

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E), Middle East respiratory syndrome-related coronavirus (MERS-CoV), influenza A virus and respiratory syncytial virus (RSV) (PubMed=37668370)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=37668370)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: TKG; TKG 0436

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E), Middle East respiratory syndrome-related coronavirus (MERS-CoV), influenza A virus and respiratory syncytial virus (RSV) (PubMed=37668370)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=37668370)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 903 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](https://www.fdi-lab.com/sci-crunch).

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.

Li F, et al. (2024) Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis. *Biology direct*, 19(1), 132.

Bai Y, et al. (2024) Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma. *iScience*, 27(6), 109997.

Shu G, et al. (2024) PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma. *Cancer research*, 84(10), 1659.

Hwang C, et al. (2024) TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment. *The American journal of pathology*, 194(7), 1306.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Serra F, et al. (2024) p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response. *Nature communications*, 15(1), 2821.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Pal SK, et al. (2024) CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. *Cancer discovery*, 14(7), 1176.

Tang G, et al. (2024) circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis. *International journal of biological macromolecules*, 256(Pt 1), 128338.

El Zarif T, et al. (2024) Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. *Cell reports*, 43(6), 114350.

Stokes ME, et al. (2023) PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(23), 4870.

Lignet F, et al. (2023) Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2. *Pharmaceutical research*, 40(12), 3011.

Takemoto K, et al. (2023) BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress-related tumorigenicity. *Cancer science*, 114(2), 436.

Takahashi M, et al. (2023) Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma. *British journal of cancer*, 129(3), 521.

Chen WJ, et al. (2023) Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma. *Cell death & disease*, 14(1), 30.

Tian J, et al. (2023) POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. *International journal of molecular sciences*, 24(7).

Tang H, et al. (2023) Histone demethylase KDM4B contributes to advanced clear cell renal carcinoma and association with copy number variations and cell cycle progression. *Epigenetics*, 18(1), 2192319.

Vaickelionien? R, et al. (2023) Synthesis of novel sulphamethoxazole derivatives and exploration of their anticancer and antimicrobial properties. *PloS one*, 18(3), e0283289.

Pan H, et al. (2023) LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma. *Medicina (Kaunas, Lithuania)*, 59(2).